TC BioPharm (TCBP) said Wednesday it executed a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company in an all-stock transaction.
The target company has a US Food and Drug Administration-approved once-per-day drop to decrease intraocular pressure and a pipeline of development-stage assets in ophthalmology indications, TC said.
The company said it expects to execute the binding letter of intent in the next 2-3 weeks and close the acquisition in Q3 of 2025.
Shares of TC BioPharm were over 8% lower in recent trading.
Price: 1.78, Change: -0.16, Percent Change: -8.25
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。